<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dirros.openscience.si/IzpisGradiva.php?id=29212"><dc:title>European prognosis evaluation of early-stage lung adenocarcinoma patterns after lobectomy versus segmentectomy based on clinical stage settings</dc:title><dc:creator>Lula,	Lukadi Joseph	(Avtor)
	</dc:creator><dc:creator>Huang,	Lin	(Avtor)
	</dc:creator><dc:creator>Forcada Barreda,	Clara	(Avtor)
	</dc:creator><dc:creator>Costa,	Rita	(Avtor)
	</dc:creator><dc:creator>Domjan,	Matic	(Avtor)
	</dc:creator><dc:creator>Franssen,	A.J.P.M.	(Avtor)
	</dc:creator><dc:creator>Jašovič,	Črt	(Avtor)
	</dc:creator><dc:creator>Štupnik,	Tomaž	(Avtor)
	</dc:creator><dc:subject>lobectomy</dc:subject><dc:subject>lung adenocarcinoma</dc:subject><dc:subject>segmentectomy</dc:subject><dc:subject>patterns</dc:subject><dc:subject>prognosis</dc:subject><dc:description>Objectives: To investigate the prognosis of peripheral early-stage lung adenocarcinoma patterns treated by lobectomy or segmentectomy. Methods: Retrospective multicentric cohort of patients with cT1a-bN0M0 lung adenocarcinoma who underwent lobectomy or segmentectomy with systematic lymph node dissection in 10 European centers (one per country) from 2015 to 2021. Overall survival (OS), disease-free survival (DFS), and lung cancer–specific death (LCSD) between both groups were assessed in entire dataset and in dataset of histologic aggressive patterns, before and after propensity score-matching (PSM). Prognostic risk factors were analyzed using parsimonious model Cox regression. Recurrences were assessed by linearized risks. Results: Lobectomy and segmentectomy were performed in 1029 (73.1%) and 377 (26.8%) patients, respectively. In total, 427 (30.3%) patients had at least 1 histologic aggressive (micropapillary or solid) pattern, and 88 patients (20.7%) underwent segmentectomy. OS, DFS, and LCSD rates were similar between patients who underwent lobectomy or segmentectomy, in both datasets, before and after PSM. In aggressive dataset, PSM, 5-year OS rates were lobectomy 88.0% (95% CI, 80.9-95.7%), segmentectomy 89.1% (95% CI, 82.2-96.6%), P = .8; 5-year DFS rates were lobectomy 79.8% (95% CI, 70.8-89.8%), segmentectomy 80.6% (95% CI, 71.6-90.6%), P = .6; and 5-year LCSD rates were lobectomy 6.0%, segmentectomy 7.8%, P = .8. Locoregional recurrence was not superior in patients who underwent segmentectomy in entire dataset (linearized risks: lobectomy 0.078, segmentectomy 0.073) and in aggressive dataset (linearized risks: lobectomy 0.036, segmentectomy 0.011) only in the unmatched cohorts. Aggressive histologic patterns impacted on only LCSD, and only when they were dominant. Conclusions: Segmentectomy seems comparable to lobectomy for patients with peripheral cT1a-bN0M0 lung adenocarcinoma even in case of histologic aggressive patterns.</dc:description><dc:date>2026</dc:date><dc:date>2026-04-24 14:06:19</dc:date><dc:type>Neznano</dc:type><dc:identifier>29212</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
